Condition: Liver Cirrhosis · Ascites Hepatic · Portal Hypertension · Sponsor: University Hospital Freiburg
The aim of this clinical trial is to compare the safety and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) implantation with standard treatment (diuretic medications, and if necessary, paracenteses) in patients with liver cirrhosis and development of ascites as the first decompensating event. By creating a shunt between the liver vein and the portal vein, blood is diverted from the portal vein directly into the hepatic vein, which results in a reduction of pressure in the portal vein so that development of ascites is reduced.
This description comes directly from the study's public registry record.
Dominik Bettinger, MD · +4976127036870 · dominik.bettinger@uniklinik-freiburg.de
Marco Janoschke, PhD · +4976127077831 · marco.janoschke@uniklinik-freiburg.de
Always discuss trial participation with your own doctor first.
| University Medical Center Freiburg | Freiburg im Breisgau, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06576934